Review of immunological and immunopathological findings in schizophrenia

Brain, Behavior, and Immunity

Volumn 15, Issue 4, 2001, Pages 319-339

  Rothermundt, Matthias ^a   Arolt, Volker ^a   Bayer, Thomas A ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Acute phase protein; Antibody; Blood brain barrier; Cytokine; Immunocompetent cell; Immunology; Immunopathology; Postmortem; Schizophrenia

Indexed keywords

ACUTE PHASE PROTEIN; ANTIBODY; AUTOANTIBODY; COMPLEMENT; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

AUTOIMMUNITY; BLOOD BRAIN BARRIER; CADAVER; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DISEASE MARKER; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGY; IMMUNOPATHOLOGY; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

EID: 0035671763     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1006/brbi.2001.0648     Document Type: Article

References (193)

1. Schizophrenic sera contain antibody against brain
2. T-cell subsets in acute psychotic schizophrenic patients
3. Cellular immunity and immune genetics in schizophrenia
4. Altered white cell count, protein concentration and olioclonal IgG bands in the cerebrospinal fluid of many patients with acute psychiatric disorders
5. Serum levels of soluble IL-2 receptor α IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration
6. Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients
7. Immunoglobulins and improvement in acute schizophrenic reactions
8. Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia
9. Recent advances in defining the neuropathology of schizophrenia
10. Production of interferon-gamma in families with multiple occurrence of schizophrenia
11. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment
12. Serum cytokine concentrations in patients with schizophrenia
13. Changes in interleukin-1β and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients
14. Tissuebinding factor in schizophrenic sera: A clinical and genetic study
15. Herpes simplex antibodies in the cerebrospinal fluid of schizophrenics patients
16. Genetic and non-genetic vulnerability factors in schizophrenia: The basis of the "Two hit hypothesis"
17. Evidence for activation of microglia in patients with psychiatric illnesses
18. Erweiterte kernspintomographische untersuchungen bei borna-disease-virus-seropositiven psychiatrischen patienten und kontrollen
19. Serum interferon in first psychotic attack
20. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients
21. Demonstration of nuclear and cytoplasmatic fluorescence in brain of schizophrenic and nonschizophrenic patients
22. Clinical and experimental observations on catatonia
23. Increased levels of CD8 + 45RA + lymphocytes in schizophrenic patients
24. Cytokines production in chronic schizophrenia patients with or without paranoid behavior
25. High seroprevalence of Borna virus infection in schizophrenic patients, family members and mental health workers in Taiwan
26. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients
27. Elevated IgG anti-histone antibodies in a subgroup of medicated schizophrenic patients
28. Obstetric complications and autoantibodies in schizophrenia
29. Serum immunoglobulin levels in chinese male schizophrenics
30. T Lymphocytes in schizophrenia
31. Quantitative determination of immunoglobulins in CSF and plasma of chronic schizophrenic patients
32. An analysis of lymphocyte subpopulations in schizophrenic patients
33. Are there antibodies against brain in sera from schizophrenic patient? Review and prospectus
34. Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients
35. Failure to detect immunologic stigmata in schizophrenia
36. Interleukin-1α and interleukin-2 in cerebrospinal fluid of schizophrenic subjects
37. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study
38. Autoimmunity and mental illness
39. The "antibrain factors" in psychiatric patients sera. I. Further studies with a hemagglutination technique
40. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia
41. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission
42. No changes in paired viral antibody titers doring the course of acute schizophrenia
43. Herpes simplex virus and cytomegalovirs in the serum of schizophrenic patients versus other psychosis and normal controls
44. Clinical and laboratory evidence of autoimmunity in acute schizophrenia
45. Decreased interleukin-2 production in schizophrenic patients
46. CD5 Positive B Lymphocytes in schizophrenia: No alteration in numbers or percentage as compared with control subjects
47. Altered interleukin-2 production in schizophrenia: Association between clinical state and autoantibody production
48. Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients
49. Autoimmunity in schizophrenia: A review of recent findings
50. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness
51. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients
52. Abnormalities in serum concentrations of interleukin-2 interferon-α and interferon-γ in schizophrenia not detected
53. Increased soluble interleukin 2 receptor levels in schizophrenia
54. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis
55. Antiretroviral antibodies: Implications for schizophrenia, schizophrenia spectrum disorders and bipolar disorder
56. Schizophrenia as an immunologic disorder. 3. Effects of antimonkey and antihuman brain antibody on brain function
57. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques
58. Antiseptal brain antibody in IgG of schizoprenic patients
59. T-Lymphocyte Subpopulations in Schizophrenic Patients
60. Antibodies to brain tissue in sera of schizophrenic patients preliminary findings
61. Increased prevalence of antibrain antibodies in the sera from schizoprenic patients
62. Monoclonal antibodies to study the brain in schizophrenia
63. Lymphokine produktion in leukocyte cultures of patients with schizophrenia
64. Clinical investigation of the relationship between Borna disease virus (BDV) infection and schizophrenia in 67 patients in Japan
65. From immoneurology to immunopsychiatry: Neuromodulating activity of anti-brain antibodies
66. Differential appearance of autoantibodies to human brain S 100 protein, neuron specific enolase and myelin basic protein in psychiatric patients
67. Cytotoxic anti-lymphocyte antibody in schizophrenics
68. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia
69. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia
70. Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia
71. Decreased interleukin-2 production in Korean schizophrenic patients
72. A survey of serum antibodies to eight common viruses in psychiatric patients
73. Serum and CSF antibody titres to seven common viruses in schizophrenic patients
74. Abnormal cerebrospinal fluid protein indices in schizophrenia
75. Infection and autoimmunity as etiologic factors in schizophrenia: A review and reappraisal
76. Quantitative determination of immunoglobulins in schizophrenics patients
77. Heterogeneity of the psychoses: Is there a neurodegenerative psychosis?
78. Circulating immune complexes and autoantibodies in schizophrenia
79. Increased serum neopterin levels in acutely ill and recovered schizophrenic patients
80. Microglia: A sensor for pathological events in the CNS
81. Cytokines and autoimmune disease
82. Detection of antibrain antibodies in the sera of patients with neuropsychiatric disorders
83. Immunoglobins, autoantibodies and other serum protein fractions in psychiatric disorders
84. Über die liquordiagnose der schizophrenien
85. Differences in the natural autoantibody patterns of patients with schizophrenia and normal individuals
86. Elevated cellular immune response to human heat-shock protein-60 in schizophrenic patients
87. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
88. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6
89. Schizophrenia an immunologic disorder
90. Antibodies to thymocytes in sera of patients with schizophrenia
91. Interleukin-1beta: A putative mediator of HPA axis hyperactivity in major depression?
92. Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine
93. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression
94. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of Neuroleptica and mood stabilizers
95. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs
96. Lymphocyte subsets in schizophrenic disorders
97. Antibodies to neuroblastoma cell line proteins in patients with schizophrenia
98. + B Lymphocytes in schizophrenic patients
99. Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status
100. Schizophrenia and autoimmune serogical reactions Arch
101. Psychoses associated with influenza
102. Influenza and schizophrenia. An analysis of postinfluenza "dementia praecox" as of 1918 and five years later
103. The schizophrenia syndrome as a produkt of acute infectious disease
104. Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy
105. Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients
106. Interferon production in blood cell cultures of schizophrenic patients
107. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment
108. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients
109. Cellular immunity in schizophrenic patients before and during neuroleptic treatment
110. T-cells and psychopathology in schizophrenia: Relationship to the outcome of neuroleptic therapy
111. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: Relationship to negative symptomatology
112. Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients
113. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia
114. Increase in expression of adhesion molecule receptors on T Helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia
115. Elevated circulating levels of IL-6 in schizophrenia
116. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia
117. Abnormal distributions of T-lymhocyte subsets in the cerebrospinal fluid of patients with akute schizophrenia
118. Accumulation of macrophages in the CSF of schizophrenic Patients during acute psychotic episodes
119. Lymphocyte subpopulations in peripheral blood from schizophrenic patients
120. Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder
121. Autoimmune model of schizophrenia with special reference to antibrain antibodies
122. Brain structure changes in schizophrenics with high serum titers of antibodies to herpes virus
123. Autoantibodies to brain lipids in schizophrenia
124. Anti-CNS antibodies in neurological and psychiatric disorders
125. Investigation of brain autoantigens in the blood serum of schizophrenics
126. + B lymphocytes in schizophrenia
127. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics
128. Increased serum ige in schizophrenic patients who responded poorly to neuroleptic treatment
129. Serum immunoglobulins and schizophrenia
130. Immunochemical profiles in schizophrenia
131. Elevated levels of soluble interleukin-2 receptors in schizophrenia
132. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins
133. Increased serum soluble interleukin-2 receptors in caucasian and korean schizophrenic patients
134. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia
135. An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients
136. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers
137. Specific IgA antibody increases in schizophrenia
138. Failure to detect Borna disease virus infection in peripheral blood leukocytes from humans with psychiatric disorders
139. Serum and CSF antibody levels to herpes simplex type 1, measles and rubella viruses in patients with schizophrenia
140. Antibrain antibodies and interferon in the serum and the cerebrospinal fluid of patients with schizophrenia
141. Serum and cerebrospinal fluid antibodies to cytomegalovirus in schizophrenia
142. Myelin basic protein antibodies in catatonic schizophrenia
143. Is there gliosis in schizophrenia? Investigation of the temporal lobe
144. Dynamic changes in the indices of the B immunity system in patients with newly diagnosed schizophrenia during treatment
145. Produktion of cytokines in acute schizophrenic psychosis
146. Immunological dysfunction in schizophrenia: A systematic approach
147. Cytokine production in unmedicated and treated schizophrenic patients
148. Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection
149. Investigation of precipitins to human brain in sera of psychotic patients
150. Kinetics of cytokine secretion by mononuclear cells of the blood in rheumatoid arthritis patients are different from those of healthy controls
151. Serum immunoglobin status of psychiatric in-patients
152. Changes of imunological functions after acute exacerbation in schizophrenia
153. Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia
154. No evidence for autoimmunity in schizophrenia
155. Studies of cellular immunity, serum interferon titers, and natural killer cell activity in schizophrenic patients
156. Antinuclear antibodies in schizophrenia and major depressive disorder - A lasting puzzle
157. Autoantibodies against 60-kDa heat shock protein in schizophrenia
158. Anticerebral antibodies in functional psychoses
159. Platelet autoantibodies in dementia and schizophrenia. Possible implication for mental disorders
160. Cytomegalovirus and schizophrenia. A test of a viral hypothesis
161. Antibodies to thymocytes in sera of normal controls and of patients with schizophrenia
162. Autoantibodies to DNA in multicase families with schizophrenia
163. Increased anti-Sm antibodies in schizophrenic patients and their families
164. Increased interleukin- 1 and interleukin-3 like activity in schizophrenic patients
165. Is schizophrenia linked to alteration in cellular immunity?
166. Neopterin production in acute schizophrenic patients: An indicator of alterations of cell-mediated immunity
167. T-cell subsets in schizophrenia: A comparison between drug-naive first episode patients and chronic schizophrenic patients
168. A study of the complement system in psychiatric patients
169. Antinuclear autoantibodies in chronic schizophrenia
170. Ganglioside antibodies in schizophrenia and major depression
171. A study of antibody levels in alcoholic, depressive and schizophrenic patients
172. Detection of anti-cerebral autoantibodies in schizophrenia and Alzheimer's disease
173. Immunoglobulin concentrations in schizophrenic patients in relation to psychopathology
174. Immunoglobins and viral antibodies in psychiatric patients
175. Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay
176. Seasonality of births in schizophrenia and bipolar disorder: A review of the literature
177. Spinal fluid monoamine metabolites and anti-aytomegalovirus antibodies and brain scan evaluation in schizophrenia
178. Decreased produktion of interleukin-2 in schizophrenia
179. Anti-histone antibodies in schizophrenia and affective disorders
180. Aberrant T-cell mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production
181. Disturbed gyrification of the prefrontal region in male schizophrenics - A morphometric postmortem study
182. Borna disease virus antibodies and the deficit syndrome of schizophrenia
183. Antihymic antibodies in schizophrenic sera
184. Implications of normal brain development for the pathogenesis of schizophrenia
185. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenics
186. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism
187. Changes of plasma concentrations of interleukin-1α and interleukin-6 with neuroleptic treatment of schizophrenia
188. Detection of borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemilumine-scence immunoassay
189. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia
190. Viruses, schizophrenia, and bipolar disorder
191. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: Markers of vulnerability or disease?
192. Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia